Source comparison
Comparison: BPC-157 vs TB-500 vs Standard Recovery Protocols
BPC-157 Protocol VEGF upregulation, collagen type I synthesis, NO pathway modulation 4–6 weeks to pain-free training Daily subcutaneous injection near injury site $120–$180 (research peptide, no insurance coverage) Accelerates tissue remodeling when combined w
This comparison does not assign a generated winner or score.
- BPC-157 Protocol
- VEGF upregulation, collagen type I synthesis, NO pathway modulation
- 4–6 weeks to pain-free training
- Daily subcutaneous injection near injury site
- $120–$180 (research peptide, no insurance coverage)
- Accelerates tissue remodeling when combined with progressive loading; no human trial data, contamination risk from unregulated sources
- TB-500 (Thymosin Beta-4)
- Actin upregulation, cell migration, anti-inflammatory cytokine modulation
- 4–8 weeks to pain-free training
- Twice-weekly subcutaneous injection (systemic)
- $200–$300 (research peptide, no insurance coverage)
- Broader systemic effects than BPC-157; some athletes report less site-specific efficacy for localized tendon injuries
- Conservative Treatment (PT + NSAIDs)
- Load management, eccentric strengthening, inflammation suppression
- 8–12 weeks to pain-free training
- Daily oral NSAIDs, 3x/week PT sessions
- $400–$800 (PT copays, medication)
- Gold standard with established safety profile; slower timeline but no regulatory or contamination concerns
- Platelet-Rich Plasma (PRP) Injection
- Growth factor delivery via autologous platelets
- 6–10 weeks to pain-free training
- Single or series of injections into tendon sheath
- $500–$1,500 per injection (insurance rarely covers)
- Evidence mixed; some tendinopathies respond well (patellar), others show no benefit over placebo (lateral epicondylitis)
- The comparison underscores a critical point: BPC-157 isn't FDA-approved, which means quality control varies wildly between suppliers. Athletes sourcing peptides from Real Peptides benefit from small-batch synthesis with verified amino-acid sequencing, but even research-grade peptides carry inherent risks when used outside clinical trials. Conservative treatment remains the lowest-risk option; peptides offer faster timelines at the cost of regulatory uncertainty.